The purpose is to see if a drug, remibrutinib 25 mg twice a day, is safe and effective in treatment of peanut, milk or egg allergy.
Participation in this study includes taking an oral investigational pill, undergoing a supervised food challenge in a clinical setting, and completing several study visits. These visits may involve blood draws, skin prick testing, an EKG (a heart rhythm test), and phone check-ins with the study team.
Clinical and Translational Research Center (CTRC)
Burnett-Womack Building (UNC-Chapel Hill)
160 Dental Cir, Chapel Hill, NC 27514, USA
Edwin Kim
Pediatrics - Allergy Immunology and Rheumatology
Clinical or Medical
Interventional
Allergy
25-1171
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
